Christopher D. Roberts

Dr. Roberts, who most recently served as Chief Scientific Officer of Black Diamond Therapeutics, offers more than 20 years of leadership experience discovering and developing novel therapies for oncology, immunology, virology, and other indications.

Prior to joining Black Diamond, Chris served as an Entrepreneur in Residence at SR One, the corporate venture capital arm of GlaxoSmithKline (GSK). Prior to SR One, Chris was the Vice President (VP) of Chemistry and Early Development at Syros Pharmaceuticals, Inc., a publicly-traded biotechnology company focused on gene control and drugging transcription, where he built and led a variety of discovery and development functions and helped guide two oncology assets into clinical development. Prior to joining Syros, Chris held numerous positions of increasing responsibility at GSK, including VP and Head of the Host Defense Discovery Performance Unit, and also led multiple clinical development projects. He joined GSK as Senior Director of Hepatitis C Virus (HCV) Medicinal Chemistry via its acquisition of Genelabs Technologies. As a medicinal chemist at Genelabs, Chris was significantly involved in establishing Genelabs’ HCV research focus. His work has been extensively published.

Chris earned a Ph.D. in Organic Chemistry from the University of California, Riverside, and completed a post-doctoral fellowship at the University of Bern, Switzerland. He graduated with a B.A. in Chemistry from Whitworth University.